Skip to main content
. 2012 Feb 15;2012(2):CD008078. doi: 10.1002/14651858.CD008078.pub2

1.25. Analysis.

1.25

Comparison 1 Anti‐leukaemic therapy plus alemtuzumab versus anti‐leukaemic therapy alone (anti‐leukaemic therapy identical in both groups; unconfounded), Outcome 25 Thrombocytopenia grade 3/4 ‐ subgrouped by starting point of alemtuzumab.